Disease Studies

Clinical Development

At PrecisionLife we’re working with leading CROs, diagnostics and pharmaceutical companies to provide better tools for stratification of patient sub-groups based on a deeper understanding of disease biology.

Our high resolution patient stratification supports selection of targets that are more likely to exhibit better efficacy in phase III trials, and recruitment of smaller and more accurately targeted clinical trials populations. It also enables development of highly predictive proprietary content that can be used as the basis of novel diagnostic and theranostic tests.


Improving target efficacy and trial design

Failure in late-stage (phase III) clinical trials is hugely expensive. Most phase III failures occur due to an inability to demonstrate efficacy rather than safety issues. This may happen when the chosen target’s biology is imperfectly mapped to the actual underlying cause of the disease for the patients enrolled in the clinical trial.

At PrecisionLife we believe that understanding the heterogeneity of target biology across responder and non-responder populations can enable early selection of targets that minimize efficacy risks in later clinical trial phases.

High resolution patient stratification also enables development of highly predictive inclusion/exclusion criteria for clinical trials. These proprietary biomarkers can also be used to guide the development of more accurate complementary diagnostic products to optimize patient outcomes.


The benefits of our approach

We analyze complex, chronic disease populations to reveal combinations of genetic variants and other clinical and epidemiological factors that act together to result in particular outcomes in specific patient sub-groups.

Our revolutionary combinatorial approach enables us to reflect the nonlinear additive biological effects caused by feedback loops in genetic and metabolic networks, which determine patients’ responses in complex, chronic diseases.

This deeper understanding of disease biology enables us to deliver:

  • More accurate prediction of a patient’s likely disease risk, prognosis and/or therapy response based on highly predictive stratification biomarkers
  • Better selection criteria for the patients most likely to respond to a new therapy, enabling smaller, faster trials with clearer outcomes and cheaper recruitment
  • Earlier de-risking of target selection to explicitly consider and avoid potential late-stage efficacy failures at a pre-clinical stage
Our approach

What we deliver

PrecisionLife engages with clinical development teams at various stages of clinical trials process, including:

  • Detailed patient stratification to identify disease subgroups and combinatorial biomarkers to be used in clinical trial design and recruitment
  • Analysis of patient registry data and RWE to identify new targets, drug repurposing opportunities and diagnostic/prognostic biomarkers
  • Identification of novel drug targets to overcome unmet medical needs for clinically relevant patient sub-groups
  • Retrospective ‘rescue’ analysis of completed clinical trials to identify responder signatures and quantify the impact they could have had on the trial’s success

Dots Dots

PrecisionLife platform overview

Chronic diseases like dementia, COPD, cardiovascular or metabolic disease don’t have simple, single gene explanations, so our patient and target selection criteria need to reflect their complexity and heterogeneity. We stratify patient sub-groups at unprecedented resolution finding new approaches to address unmet medical need and helping clinicians to select the most effective medicines.

We use our revolutionary PrecisionLife® platform to rapidly find all the combinations of genomic, phenotypic and clinical features that define disease risk, prognosis and therapy response in a complex disease population.

This enables:

  • deeper understanding of the biology of complex diseases
  • more precise patient stratification
  • identification and validation of novel targets for unmet medical needs
  • systematic analysis of drug repurposing opportunities
  • better, more personalized risk scores for complex diseases

 


How we work with you

We work with life science companies, contract research organizations and diagnostics companies in collaborative research projects. We perform in-depth analysis of a specific disease area to identify new insights around disease drivers, patient stratification biomarkers and predictive models.

We bring our PrecisionLife platform and data scientists to your clinical trials, patient populations or real-world evidence data, or we can identify suitable external patient datasets to inform our approach.

Contact us

Disease Studies

Read all Disease Studies
Pharma & Biotech
Disease Studies

Non-T2 (Non-Eosinophilic) Asthma

We revealed clear genetic differences between T2 / non-T2 asthma patients, leading to stratification biomarkers and novel, validated targets for non-T2 asthma.

Read more
Pharma & Biotech
Disease Studies

Schizophrenia

We stratified a schizophrenia patient population to identify disease sub-groups and new targets for treatment responsive and resistant groups.

Read more

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


UK

Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ

USA

1 Broadway Fl 14
Cambridge
MA 02142-1187

Denmark

Agern Allé 3
DK-2970
Hørsholm

Poland

CIC Ul
Chmielna 73m
00-801 Warszawa